Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic.
The efficacy of biological agents has been shown in several randomized clinical trials. However, little is known regarding the performance of these drugs in daily rheumatological care. Totally, 173 patients treated with biological agents (infliximab, etanercept, adalimumab, anakinra) were retrospectively analyzed between November 2001 and December 2005 at an Austrian rheumatic outpatient clinic. In total, 224 courses of treatment with biological agents were followed up. Among the 93 drug discontinuations observed, the most frequent causes were inefficacy (56.5%) and side effects (31.9%). In 74 patients (51%), the first biological agent was withdrawn after a median treatment period of 10.7 (range 0-80) months. A second biological agent was given to 36 patients, a third to 11 and a fourth to 3 patients. Our data underline the necessity of large observational studies to assess the full spectrum of patients treated with biological agents in clinical routine.
Duftner
C
C
Clinical Department of Internal Medicine, Division of General Internal Medicine, Innsbruck Medical University, Innsbruck, Austria. christina.duftner@ekh.at
Dejaco
C
C
Larcher
H
H
Schirmer
M
M
Herold
M
M
D000328:Adult; D000553:Ambulatory Care; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001317:Austria; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D012189:Retrospective Studies; D012219:Rheumatology / Q000379:methods*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome; D028761:Withholding Treatment
D018501:Antirheumatic Agents; D001688:Biological Products